[Skip to Content]
[Skip to Content Landing]
Views 1,274
Citations 0
From The Medical Letter on Drugs and Therapeutics
April 11, 2017

Lifitegrast (Xiidra) for Dry Eye Disease

Author Affiliations
 

Copyright 2017 American Medical Association. All Rights Reserved.

JAMA. 2017;317(14):1473-1474. doi:10.1001/jama.2016.12872

The FDA has approved a 5% ophthalmic solution of lifitegrast (Xiidra – Shire), a lymphocyte function-associated antigen-1 (LFA-1) antagonist, for treatment of the signs and symptoms of dry eye disease. Lifitegrast is the first LFA-1 antagonist to be approved for any indication in the US.

Ocular surface inflammation leading to dry eyes can be caused by altered tear-film composition, reduced tear production, poor lid function, environmental conditions, or diseases such as Sjögren’s syndrome. Anticholinergic drugs, estrogens, and selective serotonin reuptake inhibitors (SSRIs) can also cause dry eyes. Older age and female sex are risk factors.

First Page Preview View Large
First page PDF preview
First page PDF preview
×